Payment overview · 2025
General Payments
$359.69
11 reported records · 9 companies
Healthcare provider profile · identity verified
James V Talano, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · NAPLES, FL · NPI 1881620540
Verified facts
What the public records show
CMS Open Payments records show James V Talano, MD received $359.69 in general payments during 2025 across 11 reported records.
Edwards Lifesciences Corporation accounted for 48.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $173.09 | 48.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.50 | 18.2% | 3 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $25.86 | 7.2% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.13 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.83 | 5.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.60 | 5.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.44 | 4.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.60 | 3.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $4.64 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $359.69 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.50 | 3 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $4.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
60 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 294 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 205 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 68 |
| Eliquis | Apixaban | 182 | 52 |
| Losartan Potassium | Losartan Potassium | 158 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 136 | 45 |
| Ezetimibe | Ezetimibe | 122 | 42 |
| Furosemide | Furosemide | 109 | 45 |
| Repatha Sureclick | Evolocumab | 93 | 29 |
| Lisinopril | Lisinopril | 82 | 22 |
| Carvedilol | Carvedilol | 66 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 21 |
| Simvastatin | Simvastatin | 63 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 61 | 27 |
| Entresto | Sacubitril/Valsartan | 60 | 25 |
| Spironolactone | Spironolactone | 60 | 22 |
| Metformin Hcl | Metformin Hcl | 51 | 22 |
| Xarelto | Rivaroxaban | 51 | 15 |
| Alprazolam | Alprazolam | 50 | 23 |
| Valsartan | Valsartan | 46 | 13 |
| Ramipril | Ramipril | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 12 |
| Allopurinol | Allopurinol | 40 | 16 |
| Bumetanide | Bumetanide | 40 | 14 |
| Jardiance | Empagliflozin | 40 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 11 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 11 |
| Potassium Chloride | Potassium Chloride | 33 | 17 |
| Azithromycin | Azithromycin | 31 | 20 |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Omeprazole | Omeprazole | 30 | 11 |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 14 |
| Montelukast Sodium | Montelukast Sodium | 27 | 11 |
| Praluent Pen | Alirocumab | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 21 | suppressed |
| Progesterone | Progesterone, Micronized | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | 11 |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $359.69 · 11 records | Edwards Lifesciences Corporation | Attruby, FARXIGA, FUROSCIX, LEQVIO, LifeVest, Repatha, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error